Contrasting ReWalk Robotics (RWLK) & Delcath Systems (DCTHD)

Delcath Systems (OTCMKTS: DCTHD) and ReWalk Robotics (NASDAQ:RWLK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Delcath Systems and ReWalk Robotics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Delcath Systems -1,278.64% -3,960.73% -165.16%
ReWalk Robotics -346.14% -568.25% -90.30%

Insider and Institutional Ownership

3.2% of ReWalk Robotics shares are owned by institutional investors. 0.0% of Delcath Systems shares are owned by company insiders. Comparatively, 13.7% of ReWalk Robotics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Delcath Systems has a beta of -0.59, indicating that its share price is 159% less volatile than the S&P 500. Comparatively, ReWalk Robotics has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Earnings and Valuation

This table compares Delcath Systems and ReWalk Robotics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Delcath Systems $1.99 million 0.12 -$17.97 million ($1,377.67) 0.00
ReWalk Robotics $5.87 million 5.42 -$32.50 million ($1.59) -0.69

Delcath Systems has higher earnings, but lower revenue than ReWalk Robotics. ReWalk Robotics is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Delcath Systems and ReWalk Robotics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems 0 0 0 0 N/A
ReWalk Robotics 1 0 3 0 2.50

ReWalk Robotics has a consensus price target of $3.38, indicating a potential upside of 206.82%. Given ReWalk Robotics’ higher possible upside, analysts clearly believe ReWalk Robotics is more favorable than Delcath Systems.

Summary

ReWalk Robotics beats Delcath Systems on 11 of the 12 factors compared between the two stocks.

About Delcath Systems

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

About ReWalk Robotics

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

What are top analysts saying about Delcath Systems Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Delcath Systems Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit